Latest Industry News & Trends
Market Scope provides comprehensive coverage of the ophthalmic market. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with executives. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic industry newsletters.
Funding News
NIH Joins Push to Fund Breakthroughs in Oculomics Diagnostic Tech
The National Institutes of Health (NIH) is joining the push to fund the development of technologies and biomarkers to diagnose systemic disease through the eye, a field known as oculomics. The NIH ...
Lineage Leads Latest Ophthalmic Fundraising with $66 Million Offering
Lineage Cell Therapeutics led recent ophthalmic fundraising efforts with a registered direct offering worth up to $66 million to advance its RPE cell therapy candidate. Financing announced in the p...
ARPA-H Pledges $125 Million to Advance Whole Eye Transplantation
The Advanced Research Projects Agency for Health (ARPA-H) announced Dec. 2 that it would pledge up to $125 million from its Transplantation of Human Eye Allografts (THEA) program to advance researc...
ARPA-H Pledges $125 Million in Quest to Advance Whole Eye Transplants
The Advanced Research Projects Agency for Health (ARPA-H) announced Dec. 2 that it would pledge up to $125 million from its Transplantation of Human Eye Allografts (THEA) program to advance researc...
EyePoint Leads Latest Ophthalmic Fundraising with $161 Million Public Offering
EyePoint Pharmaceuticals led recent ophthalmic fundraising efforts with a $161 million upsized underwritten public offering. Proceeds in part will fund clinical development of Duravyu. Financing an...
November 2024 Ophthalmic News Briefs
Heidelberg Engineering announced Oct. 14 that the US FDA had granted 510(k) clearance to its Flex Module for the Spectralis diagnostic imaging platform. The Flex Module mounts the Spectralis to a m...
RevOpsis Awarded $1.8 Million NEI Grant to Advance Retinal Candidate RO-104
RevOpsis Therapeutics announced Oct. 15 that it had been awarded a Small Business Innovation Research grant of $1.8 million from the National Eye Institute (NEI) to advance lead asset RO-104 for ex...
ARPA-H Seeks Proposals for Tear Duct-Based Diagnostic System, Plus Custom Dosing Platform
ARPA-H announced Oct. 18 that it had launched a new program to develop a tear-based biomarker measurement system that can be inserted into the tear duct to provide continuous health monitoring, pai...
Grifols, BARDA Partner on Ocular Immunoglobulin Drops for Sulfur Mustard Exposure
Barcelona-basedGrifols reported Oct. 22 that it is partnering with the US government’s BARDA to test ocular surface immunoglobulin (OSIG) eye drops for their ability to treat ocular damage from sul...
Orasis Leads Latest Ophthalmic Deals with $78 Million Financing
Orasis Pharmaceuticals led recent ophthalmic fundraising efforts with $78 million in Series D and structured capital to support the launch of Qlosi drops for presbyopia. Financing announced in the ...
Investors Take Temperature of Ophthalmic Market at European Futures Forum
The 2024 Ophthalmology Futures European Forum reviewed the decline in ophthalmic deals in 2024 before offering presenting companies some guidance on how to advance their technology in such an envir...
Eyenovia Launches Clobetasol Drops for Postoperative Pain, Inflammation
Eyenovia announced Sept. 26 the US launch and commercial availability of clobetasol propionate ophthalmic suspension 0.05%, known as Clobetasol, for postoperative inflammation and pain following oc...
Boehringer Ingelheim to Advance Surrozen’s Bi-specific Antibody in Retinal Disease
Surrozen announced Sept. 24 that development partner Boehringer Ingelheim will advance SZN-413, a bi-specific antibody targeting retinal vascular disease. The milestone triggers a $10 million payme...
ONL Leads Latest Ophthalmic Fundraising with $65M Series D Round
ONL Therapeutics led recent ophthalmic fundraising efforts with a $65 million Series D round to continue advancing its small-molecule Fas inhibitor for retinal disease. Financing announced in the p...
MeiraGTx Leads Latest Ophthalmic Fundraising with $50 Million Offering
MeiraGTx led recent ophthalmic fundraising efforts with a $50 million offering of ordinary shares as it moves forward with its extensive pipeline of gene therapy candidates. Financing announced in ...
US FDA Approves Expanded Access Program for Ocugen’s RP Candidate
Ocugen announced Aug. 5 that the US FDA had approved an expanded access program to allow for the treatment of adults with retinitis pigmentosa (RP) with OCU400—a modifier gene therapy product candi...
Q2-2024 Ophthalmic Deals Total More Than $1.6 Billion, Include One Strategic Purchase
Ophthalmic deals in Q2-2024 reached over $1.6 billion and involved 19 transactions. This compares with $7.0 billion from 25 transactions in Q2-2023 and $2.0 billion from 17 transactions in Q1-2024....
Beacon Leads Latest Ophthalmic Fundraising with $170 Million in Series B
Beacon Therapeutics led recent ophthalmic fundraising efforts with $170 million in Series B funding to advance its candidates for retinal disease. Financing announced in the past four weeks totaled...
J&J Leads Series A Round for Crosslinking Tech Developer TecLens
Johnson & Johnson is the lead investor in a Series A funding round for Stamford, Connecticut-based TecLens, developer of a new crosslinking technology, J&J announced June 21. The technology is inte...
Opthea Leads Latest Fundraising with $113.2M Placement, Entitlement Offer
Opthea led recent ophthalmic fundraising efforts with a $113.2 million placement and entitlement offer, as it continues to advance its wet AMD candidate. Financing announced in the past four weeks ...
LambdaVision Reports First Closing of Seed Round to Advance Artificial Retina
LambdaVision, of Farmington, Connecticut, reported May 29 that it had secured the first closing of a seed round, let by Aurelia Foundry Fund, a fund spun out of Massachusetts Institute of Technolog...
RxSight Leads Latest Ophthalmic Fundraising with $115 Million Public Offering
RxSight led recent ophthalmic fundraising efforts with a $115 million public offering to continue commercialization of its Light Adjustable Lens portfolio. Financing announced in the past four week...
Retinal Pharmaceutical Transactions Drive Ophthalmic Deals in First Quarter of 2024
Ophthalmic deals in Q1-2024 reached over $2.1 billion and involved 20 transactions. This compares with $2.0 billion from 17 transactions in Q1-2023 and $570 million from 12 transactions in Q4-2023....
Outlook Leads Latest Ophthalmic Fundraising with $164M in Private Placements
Retinal drug developer Outlook Therapeutics led recent ophthalmic fundraising efforts with two private placements, for proceeds totaling $164 million. Financing announced in the past four weeks tot...
April 2024 Ophthalmic News Briefs
Alexion, the rare disease unit of AstraZeneca, announced March 25 that the US FDA had approved its long-acting C5 complement inhibitor Ultomiris (ravulizumab-cwvz) for adults with neuromyelitis opt...
LEP Raises Funding to Advance Glaucoma Implant Targeting Inflammation, Fibrosis
Ireland-based LEP Biomedical reported April 4 that it had closed a pre-seed funding round of €100 thousand to advance its HyaGuard platform. HyaGuard is a biodegradable, subconjunctival insert desi...
Bascom Palmer Uses $1 Million Gift to Launch Whole Eye Transplant Initiative
Bascom Palmer Eye Institute reported March 5 that it would use a $1 million donation to fast-forward its initiative to transplant a whole eye. The hospital, part of the University of Miami, said th...
Washington U. Gets up to $20M ARPA-H Grant to Create Portable OCT
Washington University in St. Louis, Missouri, announced Feb. 13 that one of its professors had been awarded a grant of up to $20 million from the Advanced Research Projects Agency for Health (ARPA-...
Ocular Tx Leads Latest Ophthalmic Fundraising with $325 Million Private Placement
Ocular Therapeutix led recent ophthalmic fundraising efforts with a $325 million private placement to advance its candidate for wet age-related macular degeneration. Financing announced in the past...
Tarsus Prices $100 Million Public Offering
Tarsus Pharmaceuticals, of Irvine, California, announced March 1 that it had priced an underwritten public offering of shares and warrants, with expected gross proceeds of $100 million. Goldman Sac...
Ocular Therapeutix Announces $325 Million Private Placement, Adds Retina Specialists to Leadership Team
Ocular Therapeutix announced Feb. 22 that it had entered into a securities purchase agreement with institutional investors for a private placement of shares, with gross proceeds of approximately $3...
Australian Research Team Receives $35 Million Grant to Develop Tissue-Engineered Cornea
Researchers in Australia announced Feb. 5 that they had received a $35 million grant from the national government’s Medical Research Future Fund to support the development of a tissue-engineered co...
Washington U. Awarded up to $20 Million Federal Grant to Create Portable OCT
Washington University in St. Louis, Missouri, announced Feb. 13 that one of its professors had been awarded a grant of up to $20 million from the Advanced Research Projects Agency for Health (ARPA-...
4DMT Leads Latest Ophthalmic Fundraising with $300 Million Public Offering
4D Molecular Therapeutics led recent ophthalmic fundraising efforts with a $300 million upsized public offering to continue advancing its retinal gene therapy candidate. Financing announced in the ...
Team Receives $35 Million Grant to Develop Tissue-Engineered Cornea
Researchers in Australia announced Feb. 5 that they had received a $35 million grant from the national government’s Medical Research Future Fund to support the development of a tissue-engineered co...
4DMT Gene Therapy Candidate Reduces Treatment Burden in Phase II Trial for Wet AMD
4D Molecular Therapeutics reported Feb. 3 that it had seen positive topline results from the Phase II PRISM trial evaluating 4D-150, an intravitreal gene therapy candidate, in wet age-related macul...
New Company Eyconis Formed to Develop Ascendis Pharma's Ophthalmology Assets
Denmark’s Ascendis Pharma announced Jan. 29 that it had founded Eyconis, a separate company to develop and commercialize its ophthalmic assets globally. The company is launching with a $150 million...
Outlook Confirms Protocol for New Trial of Ophthalmic Bevacizumab, Raises up to $172 Million in Private Placements
Outlook Therapeutics reported Jan. 23 that it had received written agreement from the US FDA confirming the protocol of a new clinical trial for ONS-5010, an ophthalmic formulation of bevacizumab, ...
Xbrane Reports Plan to Raise Up to $40.2 Million to Launch Ranibizumab Biosimilar Ximluci
Swedish biosimilar drug developer Xbrane reported Jan. 22 a rights issue of units to raise SEK 343 million ($32.8 million, converted on Jan. 22, 2024) in funding. Xbrane said the offering primarily...
Two University of Colorado Ophthalmic Researchers Receive Accelerator Grants
Two ophthalmic researchers at the University of Colorado’s Anschutz Medical Campus are among nine winners of grants from the Anschutz Acceleration Initiative, a UC Anschutz program that grants awar...
Ophthalmology Sees Large Acquisitions in 2023; Dollar Total Reaches Three-Year High
Ophthalmic deals in 2023 reached nearly $12.3 billion and included 78 transactions. This compares with $5.7 billion in 2022 and $8.5 billion in 2021. Mergers and acquisitions totaled $8.9 billion; ...
2023 in Review: SVB Failure Sparks Initial Panic in Ophthalmic Medtech Sector
Silicon Valley Bank, of Santa Clara, California, was seized by the US government on March 11, 2023, in the second largest bank failure in US history. The failure caused a great deal of initial pani...
Ji Xing Leads Latest Ophthalmic Fundraising with $162 Million in Series D Round
China’s Ji Xing Pharmaceuticals led recent ophthalmic fundraising efforts with $162 million in Series D funding to advance its pipeline, which includes five ophthalmic candidates. Financing announc...
Oxurion Avoids Bankruptcy, Will Focus on Preclinical Programs in GA
Belgium’s Oxurion announced Dec. 28 that it had avoided bankruptcy through an agreement with its main creditor, Atlas Special Opportunities. Atlas will continue to fund Oxurion under an existing 20...
Oxurion Avoids Bankruptcy, Will Focus on Preclinical Programs in GA
Belgium’s Oxurion announced Dec. 28 that it had avoided bankruptcy through an agreement with its main creditor, Atlas Special Opportunities. Atlas will continue to fund Oxurion under an existing 20...
KeraLink International Launches Cornea Accelerator, Issues $100K Challenge to Innovators
KeraLink International, a nonprofit group focused on eradicating global corneal blindness, announced Dec. 11 that it had launched a Cornea Technology Accelerator, open to entrepreneurs and innovato...
EyePoint Leads Latest Ophthalmic Fundraising with $200 Million Public Offering
EyePoint Pharmaceuticals led recent ophthalmic fundraising efforts with a $200 million upsized public offering, as it continues to advance its anti-VEGF implant for retinal disease. Financing annou...
EyeBio Leads Latest Ophthalmic Fundraising with $65 Million in Series A
EyeBio led recent ophthalmic fundraising efforts with $65 million in Series A funding to continue development of its candidate for retinal disease. Financing announced in the past four weeks totale...
Ascidian Raises $40 Million in Series A Funding, Appoints Michael Ehlers as Interim President, CEO
Ascidian Therapeutics announced Nov. 8 that it had raised $40 million in Series A extension funding from life sciences venture capital company Apple Tree Partners. Ascidian, of Boston, Massachusett...
Futures Forums Cater to Companies that Can’t Gain Limelight Elsewhere, Co-founder Says
Kuldev Singh, MD (US), co-founder of Europe’s annual Ophthalmology Futures Forums (OFF), told Market Scope in October that he takes pride in the group’s record of giving “people with new ideas who ...
Tilak Leads Latest Ophthalmic Fundraising with $10.6 Million Round
France’s Tilak Healthcare led recent ophthalmic fundraising efforts with a $10.6 million funding round for its medical video games for chronic vision disorders. Financing announced in the past four...
Paris Court Opens Safeguard Proceedings, Similar to Bankruptcy, for Pixium Vision
France’s Pixium Vision reported Oct. 9 that the Commercial Court of Paris had opened safeguard proceedings—similar to bankruptcy protection—for the company, after Pixium said it might not be able t...
Brim Leads Latest Ophthalmic Fundraising with $45.8 Million Rights Issue
Brim Biotechnologies, of Taiwan, led recent ophthalmic fundraising efforts with a $45.8 million rights issue to advance its lead dry eye candidate. Funding announced in the past four weeks totaled ...
CIRM Grants $12.4 Million to Regenerative Patch Technologies to Advance RPE Implant
The California Institute for Regenerative Medicine (CIRM) announced July 27 that it had awarded a $12.4 million grant to Regenerative Patch Technologies (RPT) to support a Phase IIb clinical trial ...
CIRM Grants $12.4 Million to Regenerative Patch Technologies to Advance RPE Implant
The California Institute for Regenerative Medicine (CIRM) announced July 27 that it had awarded a $12.4 million grant to Regenerative Patch Technologies (RPT) to support a Phase IIb clinical trial ...
Kriya Leads Latest Ophthalmic Fundraising with $150 Million in Series C
Kriya Therapeutics led recent ophthalmic fundraising efforts with $150 million in a Series C financing to advance its gene therapy candidates. Funding announced in the past four weeks totaled $456....
Want to Read the Full Article?
Already Have an Account?
Register A Corporate Account
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.